These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30178516)

  • 21. Metformin as first choice in oral diabetes treatment: the UKPDS experience.
    Holman R
    Journ Annu Diabetol Hotel Dieu; 2007; ():13-20. PubMed ID: 18613325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remogliflozin Etabonate: First Global Approval.
    Markham A
    Drugs; 2019 Jul; 79(10):1157-1161. PubMed ID: 31201711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of physician practice patterns for older adults compared to NHANES diabetes cohort on oral/other therapy.
    Shaya FT; Chirikov VV; Bron M; Howard D; Foster C; Yan X; Khanna N; Warrington VO
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):153-60. PubMed ID: 23402455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
    Chen Z; Li G
    Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin: a multitasking medication.
    Bailey CJ
    Diab Vasc Dis Res; 2008 Sep; 5(3):156. PubMed ID: 18777487
    [No Abstract]   [Full Text] [Related]  

  • 26. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in selection and timing of first-line pharmacotherapy in older patients with type 2 diabetes diagnosed between 1994 and 2006.
    Foster PD; Mamdani MM; Juurlink DN; Shah BR; Paterson JM; Gomes T
    Diabet Med; 2013 Oct; 30(10):1209-13. PubMed ID: 23586333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Anti-Diabetic Medication During the First Four Years of Treatment. A Study Based on Claims Data].
    Lappe V; Köster I; Schubert I
    Dtsch Med Wochenschr; 2017 Jan; 142(1):e1-e9. PubMed ID: 28056470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
    Greene SJ; Butler J
    Circulation; 2019 Jan; 139(2):152-154. PubMed ID: 30615507
    [No Abstract]   [Full Text] [Related]  

  • 31. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes.
    Morgan CL; Poole CD; Evans M; Barnett AH; Jenkins-Jones S; Currie CJ
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4605-12. PubMed ID: 23076348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin.
    Okahata S; Sakamoto K; Mitsumatsu T; Kondo Y; Tanaka S; Shiba T
    Diabetes Obes Metab; 2019 Feb; 21(2):388-392. PubMed ID: 30146790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to select and combine oral agents for patients with type 2 diabetes mellitus.
    Chipkin SR
    Am J Med; 2005 May; 118 Suppl 5A():4S-13S. PubMed ID: 15850548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
    MMW Fortschr Med; 2009 May; 151(19):50. PubMed ID: 19827447
    [No Abstract]   [Full Text] [Related]  

  • 35. [New fixed combination in type 2 diabetes].
    Red
    MMW Fortschr Med; 2016 Apr; 158(7):74. PubMed ID: 27071602
    [No Abstract]   [Full Text] [Related]  

  • 36. Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
    Takasu T; Hayashizaki Y; Tahara A; Kurosaki E; Takakura S
    Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):87-93. PubMed ID: 25311502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin.
    Stenlöf K; Raz I; Neutel J; Ravichandran S; Berglind N; Chen R
    Curr Med Res Opin; 2010 Oct; 26(10):2355-63. PubMed ID: 20804445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selecting among ADA/EASD tier 1 and tier 2 treatment options.
    McGill JB
    J Fam Pract; 2009 Sep; 58(9 Suppl Treating):S26-34. PubMed ID: 19744422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Guidelines for the management of diabetes mellitus type 2].
    Mediavilla Bravo JJ
    Semergen; 2014 Sep; 40 Suppl 4():11-8. PubMed ID: 25595348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ertugliflozin for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):70-72. PubMed ID: 29667948
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.